Home/Pipeline/MEV-N01

MEV-N01

Rheumatoid Arthritis

Pre-clinicalActive

Key Facts

Indication

Rheumatoid Arthritis

Phase

Pre-clinical

Status

Active

Company

Mesenbio

About Mesenbio

Mesenbio is a private, pre-clinical stage biotech developing a scalable production platform for extracellular vesicle (EV) therapeutics. Its core innovation is the FT-01 system, a clonal, immortalized mesenchymal stem cell line designed to eliminate batch-to-batch variability and enable cost-effective, clinical-grade manufacturing of EVs. The company is validating its platform through an internal proof-of-concept program, MEV-N01, for rheumatoid arthritis, while actively seeking partnerships to expand into other therapeutic areas. Mesenbio aims to establish FT-01 as the industry standard for reliable EV production.

View full company profile

Therapeutic Areas

Rheumatoid Arthritis

Other Rheumatoid Arthritis Drugs

Drug	Company	Phase	Status
Early Detection Test for Rheumatoid Arthritis	Age Labs	Development	Active
Piclidenoson (CF101)	Can Fite Biopharma	Phase II/III	Previously Active
ERNA-201	Eterna Therapeutics	Preclinical	Active Discovery/Research
Tc99m Tilmanocept	Navidea Biopharmaceuticals	Phase 2/3	Jeopardized (Bankruptcy)
Monoclonal Antibody Biosimilar (Anti‑TNF)	USV Biologics Division	Phase 1	Active
Targeted Immunotherapy for Rheumatoid Arthritis (via Arthritis4Cure)	LFB	Pre-clinical	Development (Partnership)
EYD-001 (Takinib analog)	EydisBio	Preclinical	In vivo efficacy and pilot safety in progress
LFD-200	Lifordi Immunotherapeutics	Phase 1	Active
CIT-013	Citryll	Phase 2a	Active
Restem-L	Restem	Phase 2	Active
ASIT Platform	Ahead Therapeutics	Pre-clinical	Active
AX-158	Artax Biopharma	Phase 2	Active